Table 4 Publications on the role of CDKN2B-AS1 with treatment resistance in cancer
Cancer site | Study type | Treatment | Putative function | Putative mechanism | PubMed ID |
|---|---|---|---|---|---|
Osteosarcoma | In vitro | Cisplatin | Chemoresistance | Through STAT3 and miR-125a-5p | 30777616 |
Colorectal cancer | In vitro | 5-Fluorouracil | Chemoresistance | by regulating ATP-binding cassette subfamily C member 1 through binding Let-7a | 30279206 |
Lung adenocarcinoma | In vitro | Paclitaxel | Chemoresistance | Through the mitochondrial pathway by modulating the expression of apoptosis-related protein cleaved-PARP and Bcl-2 | 28402932 |
Nasopharyngeal carcinoma | In vitro | Radiation | Radioresistance | Via functioning as a miR-125a sponge | 28402230 |
In vitro | Cisplatin | Chemoresistance | Via regulating microRNA let-7a | 28117929 | |
Multiple myeloma | Patients | Hematopoietic stem cell transplantation | Relapse | By modulating p14ARF-MDM2-p53 axis | 28150872 |
Gastric cancer | In vitro | Cisplatin and 5-fluorouracil | Multidrug resistance | Decreased the expression of MDR1 and MRP1 | 27121324 |
Bladder cancer | Â | Gemcitabine | Resistance | Through the Wnt signaling pathway | 29937935 |
laryngeal squamous cell cancer | Â | Cisplatin and paclitaxel | Â | CDKN2B-AS1 expression decrease | 25257554 |
Oral squamous cancer | Â | Cisplatin | Resistance | Via impairment of the drug transporters MRP1 and ABCC2 | 29176691 |